What Are The Functions Of Dpg & Peg In Transdermal Patches? Optimize Formulation Stability & Efficacy

Dipropylene glycol and polyethylene glycol are critical excipients used to ensure both the biological efficacy and the physical stability of reservoir-type transdermal patches. Dipropylene glycol primarily functions as a penetration enhancer that reduces skin resistance, while polyethylene glycol (PEG) serves as a plasticizer and solvent to regulate drug release kinetics and reservoir viscosity.

The synergy between these two components allows for a controlled, constant drug flux through the skin barrier while maintaining the structural integrity and shelf-life of the patch. For brand owners, selecting the precise grades of these excipients is the foundation of a high-performing, stable commercial product.

Enhancing Dermal Permeability with Dipropylene Glycol

Modifying the Stratum Corneum

Dipropylene glycol acts by infiltrating the lipid structure of the skin's stratum corneum. By temporarily altering this lipid arrangement, it effectively reduces the diffusion resistance that otherwise prevents large or hydrophobic molecules from entering the bloodstream.

Maintaining Constant Drug Flux

In a reservoir system, achieving a zero-order release rate—where the drug is delivered at a constant speed—is paramount. Dipropylene glycol ensures that once the drug bypasses the rate-controlling membrane, the skin itself does not become a bottleneck that fluctuates in permeability.

Optimizing Solubility in the Reservoir

Beyond its role in the skin, dipropylene glycol can act as a co-solvent. This helps maintain the active pharmaceutical ingredient (API) in a solubilized state within the reservoir, preventing premature crystallization that could compromise the patch's dosage accuracy.

Polyethylene Glycol: The Key to Kinetic and Physical Stability

Regulating Reservoir Viscosity

Polyethylene glycol (PEG) is utilized in various molecular weights to precisely tune the viscosity of the liquid or gel reservoir. This regulation is vital for preventing leakage and ensuring the drug remains evenly distributed throughout the patch's lifecycle.

Enhancing Polymer Flexibility

As a plasticizer, PEG intercalates between polymer chains within the patch structure. This reduces intermolecular forces, which increases the flexibility and ductility of the formulation, preventing the patch from becoming brittle or cracking during storage.

Controlling Drug Release Kinetics

PEG influences the release kinetics by acting as a secondary solvent. By adjusting the concentration and molecular weight of PEG, R&D teams can speed up or slow down how quickly the API moves from the reservoir to the rate-controlling membrane.

Understanding the Trade-offs and Challenges

Balancing Permeation and Irritation

While increasing the concentration of dipropylene glycol enhances drug delivery, it can also increase the risk of skin irritation. Formulators must find the "sweet spot" where permeability is maximized without triggering adverse dermatological reactions in patients.

Managing Plasticizer Migration

Over time, plasticizers like PEG can migrate from the reservoir into the adhesive layer. If not properly managed through stringent quality control, this can weaken the patch's "tack" and cause it to fall off the patient prematurely.

Impact of Molecular Weight

The choice of PEG molecular weight (e.g., PEG-400 vs. PEG-4000) significantly impacts the final product. Lower molecular weights provide better plasticization, while higher weights are more effective at increasing viscosity and structural rigidity.

Making the Right Choice for Your Goal

When partnering with a contract manufacturer for transdermal development, your choice of excipient strategy should align with your specific market objectives:

If your primary focus is rapid onset of action: Prioritize formulations with higher concentrations of dipropylene glycol to maximize initial skin permeation.
If your primary focus is long-term (7-day) wearability: Focus on high-molecular-weight PEG to ensure reservoir stability and prevent adhesive degradation over extended periods.
If your primary focus is maximizing shelf-life in varied climates: Ensure your R&D partner utilizes PEG as a primary plasticizer to prevent the patch from becoming brittle in cold or dry environments.

Successful transdermal product commercialization relies on the precise calibration of these excipients within a GMP-certified manufacturing framework to ensure safety, efficacy, and consumer trust.

Summary Table:

Excipient	Primary Function	Key Benefits in Formulations
Dipropylene Glycol	Penetration Enhancer	Reduces skin resistance, maintains constant drug flux, and prevents API crystallization.
Polyethylene Glycol	Plasticizer & Solvent	Regulates viscosity, prevents patch brittleness, and controls release kinetics.

Scale Your Brand with Enokon’s Advanced Transdermal Manufacturing

At Enokon, we are more than a manufacturer; we are your strategic partner in high-performance transdermal delivery. Whether you are a brand owner, wholesaler, or B2B distributor, our GMP-certified facilities and expert R&D team provide the turnkey solutions you need to lead the market.

Why Partner with Enokon?

Turnkey R&D & Custom Formulations: Expert calibration of excipients for maximum biological efficacy and physical stability.
Massive Production Capacity: Reliable high-volume delivery to meet global demand with stringent quality control.
Comprehensive Product Range: Specialized in Lidocaine, Menthol, Capsicum, Herbal, and Far Infrared pain relief, plus Eye Protection, Detox, and Medical Cooling Gel patches (excluding microneedle technology).
Global Certifications: A trusted OEM/ODM partner for well-known brands, ensuring reliability and high profit margins for distributors.

Ready to enhance your product line with a trusted manufacturer? Contact Enokon Today to discuss your wholesale requirements and custom formulation needs.

References

Hsuan-Ang Tsai, Guochuan Tsai. Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems. DOI: 10.3762/bjnano.15.42

This article is also based on technical information from Enokon Knowledge Base .